Atlas Trials

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Clinical trial NCT00740051 · COMPLETED

Trial details

NCT number
NCT00740051
Sponsor
Boehringer Ingelheim
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Diabetes Mellitus, Type 2
Start date
2008-08-01
Primary completion
2010-08-01
Enrollment
227

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.